Company: SUPN
Filing Date: 2025-02-25
Form Type: 10-K
Source: 0001356576-25-000017
Chunk: 77

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-02-25
Form: 10-K
Item: Item 1C
Chunk 77
---
1,206,812 $28.29 Exercised (781,441)$16.12 Forfeited (290,120)$31.96 Outstanding, December 31, 20246,719,073 $30.44 5.9$43,198 As of December 31, 2024Vested and expected to vest6,719,073 $30.44 5.9$43,198 Exercisable 4,137,283 $29.54 4.4$30,396 The weighted average grant date fair value of options granted for the years ended December 31, 2024, 2023, and 2022 were $16.57, $21.30, and $18.10 per share, respectively.The aggregate intrinsic value of shares exercised for the years ended December 31, 2024, 2023, and 2022 were $14.4 million, $5.1 million, and $16.3 million, respectively. Proceeds from the options exercised for the years ended December 31, 2024, 2023, and 2022 were $6.8 million, $4.3 million, and $10.4 million, respectively. The total fair value of the underlying common stock related to options that vested during the years ended December 31, 2024, 2023, and 2022 were approximately $16.7 million, $14.8 million, and $13.9 million, respectively.

Table of ContentsSupernus Pharmaceuticals, Inc.Notes to Consolidated Financial Statements (Continued)9. Share-Based Payments (Continued)

The fair value of each option award is estimated on the date of the grant, using the Black-Scholes option-pricing model and the assumptions in the following table: Year Ended December 31,202420232022Fair value of common stock$27.94 - $36.16$27.66 - $38.60$28.93 - $35.23Expected volatility55.56% - 56.55%56.87% - 58.22%58.71% - 60.15%Expected dividend yield0%0%0%Expected term5.77 years - 7.91 years5.60 years - 7.03 years5.58 years - 6.72 yearsRisk-free interest rate3.82%